TP53 and pancreatic neoplasm: Overall, ZQJ29 acts as a PARP1 inhibitor that downregulates the expression of SLC7A11 and GPX4 in a TP53‐dependent manner, thereby promoting ferroptosis in pancreatic cancer cells.